医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Kyowa Hakko Kirin Announces Marketing Authorisation Application for Mogamulizumab Validated by European Medicines Agency

2017年10月27日 PM04:00
このエントリーをはてなブックマークに追加


 

TOKYO

Kyowa Hakko Kirin Co., Ltd. (TOKYO:4151) (President and CEO: Nobuo Hanai, “Kyowa Hakko Kirin”) today announces that its marketing authorisation application (MAA) for mogamulizumab, for the treatment of cutaneous T-cell lymphoma (CTCL) in adults who have received at least one prior systemic therapy, has been validated by the European Medicines Agency (EMA) and is now under review.

This MAA is based on the data from the MAVORIC (Mogamulizumab anti-CCR4 Antibody Versus ComparatOR In CTCL) study, the largest global randomised clinical trial of systemic therapy in CTCL.

“This is a significant milestone for our subsidiary, Kyowa Kirin Pharmaceutical Development,” said Mitsuo Satoh, Ph.D., Executive Officer, Vice President Head of R&D Division of Kyowa Hakko Kirin. “I believe mogamulizumab has the potential to be an advance in therapy for patients with CTCL and we will keep working to make it available to patients as soon as possible.”

Mogamulizumab was first approved in Japan 2012 for other haematological malignancies and in 2014 for use in CTCL. Kyowa Hakko Kirin has also initiated discussions with regulatory authorities concerning plans for marketing authorisation applications for mogamulizumab in CTCL in other countries.

The Kyowa Hakko Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies.

About Mogamulizumab

Mogamulizumab is a humanised monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4), which is frequently expressed on leukemic cells of certain hematologic malignancies including CTCL. Mogamulizumab was produced using Kyowa Hakko Kirin’s proprietary POTELLIGENT® platform, which is associated with enhanced antibody-dependent cellular cytotoxicity (ADCC).

About MAVORIC

MAVORIC is a Phase 3 open-label, multi-centre, randomised study of mogamulizumab versus active comparator in patients with mycosis fungoides (MF) and Sézary syndrome (SS) who have failed at least one prior systemic treatment. The study was conducted in the US, Europe, Japan and Australia, and randomised 372 patients.

About CTCL (Cutaneous T-cell Lymphoma)

CTCL is a rare type of non-Hodgkin’s T-cell lymphoma. The two most common types of CTCL are MF and SS, and depending on the stage, the disease may involve skin, blood, lymph nodes, and viscera. In advanced stage CTCL is associated with significant morbidity and mortality.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171027005185/en/

CONTACT

Kyowa Hakko Kirin Co. Ltd.
Media
Hiroki Nakamura,
+81-3-5205-7205
media@kyowa-kirin.co.jp

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 医疗技术领袖将在世界患者安全科技峰会上讨论开放数据
  • 世界患者安全・科学・技術サミットで医療技術リーダーがオープンデータについて議論
  • 世界患者安全峰会虽然额满,但分组讨论会仍有空位,分组讨论会将于世界峰会次日在伦敦皇家学会召开
  • SPIRIT DSP: VideoMost® Helps Anet in Japan with Telemedicine and Enterprise Sales
  • 武田宣布其获2018全球杰出雇主认证